Achaogen Share Price

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/20/12	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/20/29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	6L 6L 5L 5L 9L 6Cr 9L 63.11L 25.17L 3.2Cr 23.98L 23.46L 10Cr	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	1.95Cr 1.75Cr 1.6Cr 1.46Cr 2.74Cr 182.99Cr 2.83Cr 19Cr 7.67Cr 98Cr 7.31Cr 7.15Cr 308.24Cr	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/20/12	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/20/29	Achaogen, Inc. Went Out of Business	CI
29/20/29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/20/22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/20/21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/20/30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/20/09	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/19/29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/19/24	Final DIP Financing Approved for Achaogen, Inc.	CI
29/19/29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/19/13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/19/30	Achaogen, Inc. Announces Management Changes	CI
23/19/23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	1.12Cr 1Cr 91.6L 83.62L 1.58Cr 105.05Cr 1.63Cr 11Cr 4.4Cr 56Cr 4.19Cr 4.1Cr 176.95Cr	87.28L 78.28L 71.54L 65.31L 1.23Cr 82Cr 1.27Cr 8.62Cr 3.44Cr 44Cr 3.28Cr 3.21Cr 138.2Cr
Net income	-13Cr -11Cr -10Cr -9.4Cr -18Cr -1.18TCr -18Cr -124.11Cr -49Cr -630.07Cr -47Cr -46Cr -1.99TCr	-19Cr -17Cr -15Cr -14Cr -26Cr -1.75TCr -27Cr -184.28Cr -73Cr -935.5Cr -70Cr -69Cr -2.95TCr
Net Debt	-14Cr -13Cr -12Cr -11Cr -20Cr -1.34TCr -21Cr -141.12Cr -56Cr -716.42Cr -54Cr -52Cr -2.26TCr	1.88Cr 1.69Cr 1.54Cr 1.41Cr 2.65Cr 176.99Cr 2.74Cr 19Cr 7.42Cr 94Cr 7.07Cr 6.92Cr 298.13Cr

Achaogen Share Price

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile